percutaneous transluminal angioplasty

Interview

07/19/2021

William A. Gray, MD¹; Christopher J. White, MD²

¹Main Line Health, Lankenau Heart Group, Wynnewood, Pennsylvania; ²Ochsner Medical Center, New Orleans, Louisiana

William A. Gray, MD1; Christopher J. ...

A brief trial summary and interviews with William A. Gray, MD, and Christopher J. White, MD, regarding the DISRUPT PAD trial.

A brief trial summary and...

07/19/2021

Vascular Disease Management

EP Tips & Techniques

Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial

07/23/2019

Jihad A. Mustapha, MD¹; Marianne Brodmann, MD²; Patrick J. Geraghty, MD³; Fadi Saab, MD¹; Richard A. Settlage, MS⁴; Michael R. Jaff, DO⁵; on behalf of the Lutonix BTK Study Investigators

Jihad A. Mustapha, MD1; Marianne Bro...

We hypothesized that a drug-coated balloon could improve treatment efficacy while maintaining safety when compared with percutaneous transluminal angioplasty for the treatment of atherosclerotic infrapopliteal arterial lesions.

We hypothesized that a...

07/23/2019

Journal of Invasive Cardiology

Case Series

Hemorrhage After Percutaneous Transluminal Angioplasty Localized in the Lateral Abdominal Wall: A Rare Location

12/31/2010

Roy J. Sauren, MD
Department of Surgery, Amphia Hospital, Breda, The Netherlands

Roy J. Sauren, MD Department of Surge...

The authors report on 3 female patients who presented with complaints of peripheral vascular occlusive disease. Duplex and magnetic resonance imaging showed stenosis or occlusion of an iliac or more distal artery.

The authors report on 3 female...

12/31/2010

Vascular Disease Management